Perseus Proteomics Inc

Perseus Proteomics Inc maintains a strong liquidity position, with cash and equivalents amounting to ¥1,667.92 million, representing 91.7% of total assets. The company has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative capital structure. The current ratio of 14.22 suggests a high ability to meet short-term obligations. The company is currently unprofitable, with a net loss of ¥904.80 million and an operating loss of ¥898.94 million. Return on equity is -63.17%, and return on assets is -49.75%, both significantly below the typical performance of the biotechnology industry. Gross profit of ¥104.05 million is insufficient to cover operating expenses, highlighting the need for cost optimization or revenue growth. Revenue is concentrated in a single business segment, as disclosed in the financial snapshot, with no geographic breakdown provided. This lack of diversification increases exposure to market-specific risks. The company does not report revenue by geographic region, making it difficult to assess regional performance or concentration. Outlook for the current fiscal year is negative, with no revenue growth expected. The company has not provided forward-looking guidance, and historical data shows a decline in operating and free cash flow. Analysts have issued a single "buy" recommendation, with a mean price target of ¥750.00, but no strong buy or hold ratings. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flow from operations and free cash flow of -¥977.11 million suggest potential future liquidity constraints. No dilution sources were identified in recent filings, and the dilution potential is currently low. Recent events include the publication of the latest financial results, which show a significant net loss and negative operating cash flow. No material regulatory or legal events were disclosed in the provided data. The company has not issued new shares or announced capital-raising activities in the latest reporting period.